Discontinued — last reported Q3 '23
Products & Services · Finite-Lived Intangible Assets, Net
Imbruvica — Finite-Lived Intangible Assets, Net
AbbVie Imbruvica — Finite-Lived Intangible Assets, Net decreased by 55.8% to $1.90B in Q3 2023 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ3 2023
Rolls up toIntangible assets — net
How to read this metric
A steady or increasing value suggests continued investment in the asset, while a sharp decline may indicate rapid amortization or significant impairment.
Detailed definition
This represents the net book value of finite-lived intangible assets associated with the Imbruvica product line after ac...
Peer comparison
Comparable to 'Net Intangible Assets' for specific product lines or acquired drug portfolios at peer firms.
Metric ID:
abbv_segment_imbruvica_finite_lived_intangible_assets_netHistorical Data
3 periods
| Q1 '23 | Q2 '23 | Q3 '23 | |
|---|---|---|---|
| Value | $4.80B | $4.30B | $1.90B |
| QoQ Change | — | -10.4% | -55.8% |
Range$1.90B – $4.80B
Current Streak2+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's imbruvica — finite-lived intangible assets, net?
- AbbVie (ABBV) reported imbruvica — finite-lived intangible assets, net of $1.90B in Q3 2023.
- What does imbruvica — finite-lived intangible assets, net mean?
- The current net book value of the intangible assets associated with the Imbruvica product line.